ELEVATE-TN: Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve CLL - Four-year follow up

CLL14: Venetoclax plus obinutuzumab in untreated CLL

IMpower010: Atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC

Clinically sufficient vitamin D levels at breast cancer diagnosis and survival outcomes

AL3818 hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma

Afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma

CAPTIVATE: Fixed-duration first-line treatment with ibrutinib plus venetoclax for CLL/SLL

CHRONOS: Anti-EGFR rechallenge therapy with panitumumab driven by ctDNA molecular selection in mCC

Adjuvant chemo following chemoradiation as treatment for locally advanced cervical cancer compared to chemoradiation alone

Tislelizumab in oesophageal cancer after systemic therapy

HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in MIBC patients

CodeBreaK100: Sotorasib in pretreated KRAS p.G12C mNSCLC